SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

The 2019 dyslipidaemia guideline of the ESC/EAS and the availability of the LDL-cholesterol goal attainment in very high risk patients after myocardial infarction

█ Review

DOI: 10.26430/CHUNGARICA.2020.50.4.298

Márk László1, Reiber István2, Bajnok László3
1Békés Megyei Központi Kórház, Pándy Kálmán Tagkórház, Kardiológia Osztály, Gyula
2Fejér Megyei Szent György Egyetemi Oktató Kórház, Székesfehérvár
3Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika, Endokrinológiai és
Anyagcsere Tanszék, Pécs
Levelezési cím:
Dr. Márk László, Békés Megyei Központi Kórház, Pándy Kálmán Tagkórház, Kardiológia Osztály
5700 Gyula, Semmelweis u. 1. E-mail:

The new dyslipidaemia guideline of the European Society of Cardiology and European Atherosclerosis Society was published on autumn of 2019. Its novelty was that based on the studies of the latest 3 years the LDL-cholesterol target level had been decreased. Being aware of the present daily practice for the attainment of the new goals more attention has to be paid by the doctors and would require a better adherence from patients. It has to be underlined that the achievement of 1.4 mmol/l LDL-cholesterol level or that of 1.0 mmol/l in the case of recurrent cardiovascular event within 2 years is a great challenge for the statin and combined statin+ezetimibe therapy as well. Beside the more frequent administration of the ezetimibe the use of PCSK9-inhibitors would be needed. These statements are highly valid for the patients after myocardial infarction and percutaneous intervention since they would expect most benefit from an adequate lipid lowering therapy.


click here to read the full article

click here to read the pdf